Literature DB >> 1641113

Aggressive oligodendroglioma: a chemosensitive tumor.

J G Cairncross1, D R Macdonald, D A Ramsay.   

Abstract

Aggressive oligodendrogliomas, tumors that are symptomatic, enlarging, enhancing, and usually but not always anaplastic, respond to chemotherapy. We have observed responses to chemotherapy in 18 of 19 consecutively treated patients with newly diagnosed or recurrent aggressive oligodendrogliomas. A regimen of procarbazine, CCNU (lomustine), and vincristine (PCV) is predictably effective, but other drugs have antioligodendroglioma activity. Cooperative group trials will be necessary to determine the most effective drug, or combination of drugs, and to explore fully the role of chemotherapy in the treatment of this uncommon glioma.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1641113     DOI： 10.1227/00006123-199207000-00011

Source DB:  PubMed          Journal:  Neurosurgery        ISSN： 0148-396X            Impact factor:   4.654


  23 in total

Review 1.  PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI.

Authors:  S Diabira; M C Rousselet; E Gamelin; P Soulier; E Jadaud; P Menei
Journal:  J Neurooncol       Date:  2001-10       Impact factor: 4.130

2.  Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?

Authors:  Matthew L White; Yan Zhang; Patricia Kirby; Timothy C Ryken
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

3.  Cerebral oligodendrogliomas in children: an analysis of 15 cases.

Authors:  T Rizk; C Mottolèse; E Bouffet; A Jouvet; J Guyotat; P Bret; C Lapras
Journal:  Childs Nerv Syst       Date:  1996-09       Impact factor: 1.475

4.  Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402.

Authors:  Meihua Wang; Gregory Cairncross; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Minesh Mehta; Walter Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-23       Impact factor: 7.038

5.  Novel drug delivery system using thermoreversible gelation polymer for malignant glioma.

Authors:  Takao Arai; Tatsuhiro Joki; Masaharu Akiyama; Miyuki Agawa; Yuichi Mori; Hiroshi Yoshioka; Toshiaki Abe
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

Review 6.  Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.

Authors:  Martin J van den Bent
Journal:  Neuro Oncol       Date:  2014-10-29       Impact factor: 12.300

7.  Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.

Authors:  Ali Chahlavi; Andrew Kanner; David Peereboom; Susan M Staugaitis; Paul Elson; Gene Barnett
Journal:  J Neurooncol       Date:  2003-02       Impact factor: 4.130

8.  Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography.

Authors:  T Kato; J Shinoda; N Nakayama; K Miwa; A Okumura; H Yano; S Yoshimura; T Maruyama; Y Muragaki; T Iwama
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-03       Impact factor: 3.825

9.  The treatment of cerebral oligodendrogliomas with particular reference to features indicating malignancy: report of seventy-seven cases.

Authors:  M Turgut; K Tahta; O E Ozcan; B Onol
Journal:  Neurosurg Rev       Date:  1998       Impact factor: 3.042

10.  Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas.

Authors:  Hideaki Yokoo; Sumihito Nobusawa; Hirohide Takebayashi; Kazuhiro Ikenaka; Koji Isoda; Makoto Kamiya; Atsushi Sasaki; Junko Hirato; Yoichi Nakazato
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.